REGAINE ® - Minoxidil

REGAINE ® is a drug based on Mioxidil

THERAPEUTIC GROUP: Dermatological preparations for local use

IndicationsAction mechanismStudies and clinical effectiveness Usage and dosage instructionsWarnings Pregnancy and lactationInteractionsContraindicationsUndesirable effects

Indications REGAINE ® - Minoxidil

REGAINE ® is a topical drug used in the treatment of androgenetic alopecia, with the intent to counteract the progressive thinning of the scalp.

Mechanism of action REGAINE ® - Minoxidil

Although minoxidil was born as an active antihypertensive ingredient, given its ability to inhibit the contraction of arteriolar smooth muscle cells, it is now marketed in the dermatological field in the treatment of androgenetic alopecia.

What was one of the side effects of anti-hypertensive therapy with minoxidil, or hirsutism, today represents the main mechanism of action that makes this active ingredient, together with finasteride, the first choice therapy for the treatment of androgenetic alopecia.

The use of REGAINE ® for topical use makes it possible to accentuate the dermatological effects by reducing the potential systemic side effects of its active ingredient.

Studies carried out and clinical efficacy

1. MINOXIDIL 5% and 2% COMPARED

The daily administration of 1 ml of 5% minoxidil proved to be just as effective and safe compared to the daily 1 ml of 2%, even contributing to the overall improvement of the aesthetic aspect.

2. CUTANEOUS ABSORPTION OF MINOXIDIL

Very interesting study that has shown how the absorption of minoxidil can take place mainly with respect to stem cells adjacent to the hair follicle, through a dense capillary network that surrounds the bulb.

3. CAUSES OF INSUCCESS OF THE THERAPY WITH MINOXIDIL

Work focusing on the causes of failure of minoxidil therapy for the treatment of androgenetic alopecia. The main cause of failure seems to be linked to the need for a long period of treatment, which unfortunately in most cases is not respected.

Method of use and dosage

REGAINE ®

Topical solution with 5% minoxidil:

the dosage scheme for the treatment of androgenetic alopecia, provides for the topical administration of one ml of REGAINE ® twice a day, exclusively on the areas affected by baldness.

Therapeutic effects should be observed approximately 3-4 months after starting treatment.

In any case, the format, the dosage and the timing of intake must be defined by your doctor together with all the hygiene rules to be followed to avoid the spread of the active ingredient in the environment.

Warnings REGAINE ® - Minoxidil

Before applying REGAINE ® it is necessary to verify the integrity of the skin and the absence of any lesions or irritations, capable of increasing the systemic absorption of minoxidil with the consequent increase in cardiovascular side effects.

In this regard, the subsequent appearance of skin reactions or cardiovascular symptoms should be immediately reported to your doctor, who should eventually consider the need to suspend therapy.

Prolonged use at high doses could bring about positive anti-doping tests due to the high concentration of REGAINE ® alcohol

PREGNANCY AND BREASTFEEDING

The use of REGAINE ® is contraindicated during pregnancy and the subsequent period of breastfeeding, given the absence of studies able to accurately define the safety profile of minoxidil when taken during pregnancy.

However, it is necessary to remember how this active ingredient is able to pass through the breast filter concentrating in breast milk.

Interactions

There are currently no pharmacokinetic studies able to define active ingredients capable of interfering with minoxidil, taken topically.

However, it is useful to remember that this active principle could determine an enhancement of the antihypertensive activity of vasodilators, increasing the episodes of orthostatic hypotension.

Contraindications REGAINE ® - Minoxidil

The use of REGAINE ® is contraindicated in case of coronary heart disease, arrhythmias, congestive heart failure, valvulopathies and medium to severe cardiovascular diseases.

REGAINE ® should also be avoided in case of hypersensitivity to the active ingredient or to one of its excipients.

Undesirable effects - Side effects

Topical use of minoxidil exposes the patient to mainly cutaneous side effects.

Dermatological reactions such as irritation, dehydration, desquamation, dermatitis, erythema appear to occur more frequently, but fortunately with the same clinical severity, in patients undergoing therapy with 5% minoxidil solutions compared to 2%.

Systemic effects such as changes in blood pressure, changes in heart rate, chest pains, liver, kidney and erectile dysfunction have occurred very rarely and usually in predisposed patients.